Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute?
Download full text from publisherTo our knowledge, this item is not available for download. To find whether it is available, there are three options:
1. Check below whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
Other versions of this item:
- William Jack & Jean O. Lanjouw, 2003. "Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute?," Working Papers 28, Center for Global Development.
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Fabio Pammolli & Armando Rungi, 2016. "Access to Medicines and European Market Integration," Working Papers 01/2016, IMT Institute for Advanced Studies Lucca, revised Jan 2016.
- Banri ITO & Tatsufumi YAMAGATA, 2007.
"Who Develops Innovations In Medicine For The Poor? Trends In Patent Applications Related To Medicines For Hiv/Aids, Tuberculosis, Malaria, And Neglected Diseases,"
The Developing Economies,
Institute of Developing Economies, vol. 45(2), pages 141-171.
- Ito, Banri & Yamagata, Tatsufumi, 2005. "Who Develops Innovations in Medicine for the Poor? Trends in Patent Applications Related to Medicines for HIV/AIDS, Tuberculosis, Malaria and Neglected Diseases," IDE Discussion Papers 24, Institute of Developing Economies, Japan External Trade Organization(JETRO).
- Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015.
"Vergleichbarkeit internationaler Arzneimittelpreise,"
Perspektiven der Wirtschaftspolitik,
De Gruyter, vol. 16(2), pages 164-172, June.
- Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015.
"Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context,"
John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
- Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012. "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers 18593, National Bureau of Economic Research, Inc.
- Pedro Pita Barros & Xavier Martínez-Giralt, 2006. "On insurance and the cost-sharing of pharmaceutical R&D," Working Papers 293, Barcelona Graduate School of Economics.
- Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015.
"Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement,"
John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
- Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers 17174, National Bureau of Economic Research, Inc.
- Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
- Michael Stolpe, 2003. "Weltweiter Patentschutz für pharmazeutische Innovationen: Gibt es sozialverträgliche Alternativen?," Perspektiven der Wirtschaftspolitik, Verein für Socialpolitik, vol. 4(4), pages 437-448, November.
- Pedro Barros & Xavier Martinez-Giralt, 2008. "On international cost-sharing of pharmaceutical R&D," International Journal of Health Economics and Management, Springer, vol. 8(4), pages 301-312, December.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters,in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
More about this item
- O32 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Management of Technological Innovation and R&D
- D42 - Microeconomics - - Market Structure, Pricing, and Design - - - Monopoly
- D40 - Microeconomics - - Market Structure, Pricing, and Design - - - General
- D63 - Microeconomics - - Welfare Economics - - - Equity, Justice, Inequality, and Other Normative Criteria and Measurement
- I12 - Health, Education, and Welfare - - Health - - - Health Behavior
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:wbecrv:v:19:y:2005:i:1:p:45-67. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Oxford University Press) or (Christopher F. Baum). General contact details of provider: http://edirc.repec.org/data/wrldbus.html .
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.